Sci Show: iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy. Multidosing to treat metastatic cancer is now FDA approved and phase I of human trials is beginning.

Monday, January 4, 2021

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti–PD-1 therapy. Multidosing to treat metastatic cancer is now FDA approved and phase I of human trials is beginning.

https://ift.tt/369dgKF via /r/science https://ift.tt/3oewW7O

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)